NEW YORK (GenomeWeb) – Molecular diagnostics developer DiaCarta announced today that its DiaCarta Clinical Services Laboratory has successfully passed the State of California survey under the Clinical Laboratory Improvement Amendments of 1988.

The lab now has permission to begin offering patient and clinical testing services for its QClamp-based molecular diagnostic. QClamp screens for tumor oncogenic driver and resistance mutations in tumor DNA derived from cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.